HES2 and uterine cancer: Esophageal cancer patients with high expression of FOXN1, GRHL3, and HES2 (Figure 7C), stomach cancer patients with high expression of ONECUT2 (Figure 7D), thyroid cancer patients with high expression of PAX8 (Figure 7E), and uterine cancer patients that expressed elevated levels of MECOM (Figure 7F) had decreased survival.